STOCK TITAN

Sana Biotechnology, Inc. - SANA STOCK NEWS

Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.

Sana Biotechnology, Inc. (NASDAQ: SANA) is a cutting-edge biotechnology company dedicated to the development of engineered cells as medicines to treat various diseases. Sana's primary focus is on cell and gene therapy, aiming to harness the potential of engineered cells to bring about transformative changes in healthcare.

The company is advancing a range of innovative therapeutic programs across multiple indications with unmet medical needs. Some of the key areas of focus include oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system (CNS) disorders. Sana's pipeline includes promising candidates such as SC291, SC262, SC255, and UP421, which are at various stages of development.

Recent Achievements and Projects:

  • Hypoimmune Technology: Sana's proprietary hypoimmune (HIP) platform is designed to create cells that can evade the patient’s immune system, allowing for the transplant of allogeneic cells without the need for immunosuppression.
  • CAR T Cell Therapies: The company is developing novel CAR T cell therapies for various cancers and autoimmune diseases. Preclinical data have shown that HIP-modified CAR T cells can avoid immune detection while retaining their functionality and anti-tumor effects.
  • Pluripotent Stem Cells: Sana is also focused on differentiating pluripotent stem cells ex vivo into immune-cloaked functional cells, aiming to replace any missing or damaged cells in the body.
  • Preclinical and Clinical Studies: In recent studies, Sana has demonstrated significant progress, such as the successful evasion of immune detection by HIP-modified CAR T cells and the potential for HIP-modified pancreatic islet cells to achieve insulin independence in diabetic models.
  • Partnerships: The company collaborates with leading research institutions and organizations to further its mission of developing next-generation cell and gene therapies.

Sana Biotechnology operates out of multiple locations, including Seattle, Cambridge, South San Francisco, and Rochester, and is committed to advancing its pipeline of therapies to address critical healthcare challenges.

Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) announced that four abstracts, including a late-breaking abstract, have been accepted for poster presentation at the 2023 AACR Annual Meeting. This meeting will take place from April 14-19, 2023, in Orlando, FL. The late-breaking abstract, titled "Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells", is set for presentation on April 19, 2023. Other significant abstracts include studies on modulation of T cell status and the development of a human anti-CD19 CAR for in vivo delivery via fusosomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary

Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the Cowen 43rd Annual Health Care Conference, scheduled for March 8, 2023, at 9:50 a.m. ET. The presentation will be led by CEO Steve Harr and will provide insights into the company's business strategy and developments in engineered cell therapies. Interested parties can access the live webcast via Sana's Investor Relations page, with a replay available for 30 days post-conference. Sana aims to revolutionize disease treatment through engineered cells, with operations in key U.S. cities including Seattle and Cambridge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences
-
Rhea-AI Summary

Sana Biotechnology, Inc. (NASDAQ: SANA) will present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference on February 9, 2023, at 1:00 p.m. ET. The presentation, led by CEO Steve Harr, will offer a business overview and update. Interested parties can access the live webcast on Sana's Investor Relations page and view a replay for 30 days post-conference. Founded to create engineered cell therapies, Sana aims to revolutionize disease treatment. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
conferences
Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) announced FDA clearance for its SC291 Investigational New Drug (IND) application, allowing a first-in-human study focusing on B-cell malignancies. SC291, a CD19-targeted allogeneic CAR T cell therapy, utilizes Sana's hypoimmune platform designed to evade immune rejection, potentially increasing treatment efficacy. The company aims to report initial clinical data later this year and is also working on a second IND for SC262, targeting CD22. CEO Steve Harr emphasized the importance of SC291 in providing new options for difficult cancers and highlighted the platform's broader applications, including treatments for type 1 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. CEO Steve Harr will provide a business overview during the webcast, accessible via Sana's Investor Relations page. A replay will be available for 30 days. Sana focuses on engineered cell therapies aimed at repairing and controlling genes and replacing damaged cells. The company operates in Seattle, Cambridge, South San Francisco, and Rochester.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
conferences
-
Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) presented data at the 64th American Society of Hematology Annual Meeting, showcasing advancements in its hypoimmune CAR T cell programs. The HIP platform, designed to evade immune detection, demonstrated efficacy in eradicating CD19+ tumors in preclinical models. Key highlights included the scalable production of CAR T cells using CRISPR/Cas12b and promising results for dual-targeted therapies against BCMA and CD19. Sana plans to file three IND applications in the coming years, starting with SC291 targeting CD19-positive cancers in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
none
Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) has announced a strategic portfolio prioritization aimed at optimizing clinical development and maintaining a strong cash runway into 2025. The company anticipates filing Investigational New Drug (IND) applications for SC291, SG295, and SC263 in 2023, while SC451 and a BCMA-targeted CAR T candidate are scheduled for 2024. However, internal investment in the SC187 program will be discontinued, resulting in a 15% workforce reduction. The firm remains committed to advancing its key clinical programs and improving its engineered cell therapies for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
none
-
Rhea-AI Summary

Sana Biotechnology (NASDAQ: SANA) announced that it will present six abstracts, including two oral presentations, at the upcoming 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans, LA. The presentations will highlight the potential of Sana's allogeneic CAR T cell and in vivo delivery platforms for treating hematologic malignancies. Key topics include CD19, CD22, and BCMA-targeted therapeutics. The company aims to advance therapies for lymphoma, leukemia, and multiple myeloma, with a focus on innovative approaches to enhance therapeutic efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.94%
Tags
Rhea-AI Summary

Sana Biotechnology, Inc. (NASDAQ: SANA) reported Q3 2022 results, highlighting a cash position of $511.6 million. The company expects to file IND applications for SC291 and SC276 in 2023, with clinical data following. Research and development expenses rose significantly to $76.7 million due to increased headcount and third-party manufacturing costs. Net loss for the quarter was $85.1 million, slightly worse than in 2021. Despite these losses, Sana maintains a robust cash runway into 2025, supporting ongoing development of its innovative CAR T therapies and hypoimmune platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.94%
Tags

FAQ

What is the current stock price of Sana Biotechnology (SANA)?

The current stock price of Sana Biotechnology (SANA) is $2.61 as of February 28, 2025.

What is the market cap of Sana Biotechnology (SANA)?

The market cap of Sana Biotechnology (SANA) is approximately 578.3M.

What does Sana Biotechnology, Inc. do?

Sana Biotechnology develops engineered cells as medicines and therapies to treat a wide range of diseases, including cancer, diabetes, and autoimmune disorders.

What is the company's primary focus?

Sana focuses on cell and gene therapy, leveraging proprietary technologies to create transformative treatments for unmet medical needs.

What is the hypoimmune (HIP) platform?

The HIP platform is designed to create cells that can evade the patient's immune system, allowing for the transplant of allogeneic cells without the need for immunosuppression.

What are some of Sana's key therapeutic areas?

Sana's key therapeutic areas include oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system (CNS) disorders.

What recent achievements has Sana Biotechnology made?

Recent achievements include preclinical data showing the immune evasion and anti-tumor effects of HIP-modified CAR T cells, and progress with stem cell-derived pancreatic islet cells for treating diabetes.

Where is Sana Biotechnology located?

Sana Biotechnology operates in Seattle, Cambridge, South San Francisco, and Rochester.

What is SC262?

SC262 is a hypoimmune, CD22-directed allogeneic CAR T cell therapy aimed at treating B-cell malignancies in patients who have failed previous CD19-directed therapies.

What is the significance of the hypoimmune platform?

The hypoimmune platform allows for the creation of allogeneic cells that can evade immune detection, potentially enabling sustained therapeutic effects without the need for immunosuppression.

How is Sana Biotechnology advancing its CAR T cell therapies?

Sana is developing CAR T cell therapies for cancers and autoimmune diseases, with promising preclinical data showing sustained immune evasion and anti-tumor effects.

How can I find more information about Sana Biotechnology?

For more information, please visit the company's official website at https://sana.com/.
Sana Biotechnology, Inc.

Nasdaq:SANA

SANA Rankings

SANA Stock Data

578.27M
203.40M
8.64%
92.51%
22.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SEATTLE